In short
This article discusses clinical trials using a novel treatment approach for newly diagnosed glioblastoma, a type of brain cancer. The treatment involves using a patient's own immune cells, specifically mature dendritic cells loaded with the patient's tumor lysate, as a vaccine. This personalized immunotherapy is being studied in combination with standard treatments to potentially improve survival outcomes for glioblastoma patients.
At a glance
- Trial Type
- Phase II clinical trial
- Condition
- Newly diagnosed glioblastoma
- Treatment
- Autologous mature dendritic cells loaded with autologous tumor lysate vaccine
- Administration
- Intradermal injection
- Primary Endpoint
- Overall survival from day of surgery until death
- Secondary Endpoints
- Progression-free survival, survival rates at 6, 12, and 24 months, safety profile, overall and neurological performance, quality of life
- Key Inclusion Criteria
- Newly diagnosed GBM, near-complete resection, sufficient tumor sample for vaccine production
- Key Exclusion Criteria
- Severe medical conditions, immunosuppression, chronic renal disease, uncontrolled cardiovascular issues, severe diabetes
What is Autologous Mature Dendritic Cells Loaded with Autologous Tumor Lysate?
Autologous Mature Dendritic Cells Loaded with Autologous Tumor Lysate is a type of personalized cancer vaccine. This treatment, also known by its sponsor product code "GlioVax," is designed to harness the power of your own immune system to fight cancer. Let's break down what this means:
- Autologous: This means the treatment is made from your own cells and tissues.
- Mature Dendritic Cells: These are special immune cells that help your body recognize and fight off harmful substances, including cancer cells.
- Tumor Lysate: This is a solution containing broken-down tumor cells from your own cancer.
How Does It Work?
The treatment works by "training" your immune system to recognize and attack your specific cancer cells. Here's a simplified explanation of the process:
- During surgery to remove your tumor, a sample of the tumor is collected.
- Scientists extract dendritic cells from your blood.
- In the lab, they expose these dendritic cells to the broken-down tumor cells (tumor lysate).
- This "teaches" the dendritic cells to recognize your specific cancer cells as threats.
- The prepared vaccine is then injected back into your body, where it helps your immune system identify and attack the cancer cells.
What Condition Does It Treat?
This treatment is being studied for newly diagnosed glioblastoma. Glioblastoma is a type of brain cancer that forms from glial cells (cells that support and protect nerve cells). It's considered a grade IV tumor, which means it's an aggressive cancer that can grow and spread quickly.
Current Clinical Trial
A Phase II clinical trial is currently underway to test this treatment. The trial is titled "Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma".
In this trial, the vaccine is being tested as an add-on to the standard treatment for glioblastoma, which includes:
- Surgery to remove as much of the tumor as possible
- Radiation therapy
- Chemotherapy with a drug called temozolomide
Who Can Participate in the Trial?
The trial has specific criteria for who can participate. Some key points include:
- Patients must have newly diagnosed glioblastoma, confirmed by a specialist.
- The tumor must be mostly removed during surgery (less than 5 ml remaining).
- A sterile tumor sample of at least 150 mg must be available to make the vaccine.
There are also conditions that might prevent someone from participating, such as certain other medical conditions or planned major surgeries.
What Are the Trial Objectives?
The main goal of the trial is to see if adding this vaccine to standard treatment helps patients live longer. Researchers will measure this by comparing how long patients who receive the vaccine live compared to those who only receive standard treatment.
Other objectives include:
- Measuring how long patients live without their cancer getting worse (called progression-free survival)
- Comparing survival rates at 6, 12, and 24 months
- Assessing the safety of the treatment
- Evaluating patients' overall health and brain function
- Assessing patients' quality of life
Safety Monitoring and Quality of Life Assessment
The trial includes careful monitoring of side effects and how well patients tolerate the treatment. Researchers will track any adverse events and grade their severity according to standardized criteria.
They will also assess patients' overall health and brain function using specific tests (KPS and MMSE-2). Quality of life will be measured using questionnaires that look at general well-being, symptoms specific to brain tumors, and psychological stress.